Last reviewed · How we verify
Aspirin 100 mg
At a glance
| Generic name | Aspirin 100 mg |
|---|---|
| Also known as | baseline background treatment |
| Sponsor | University Hospital of Ferrara |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma (PHASE2)
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (PHASE4)
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Impact of First-trimester Preeclampsia Screening on Perinatal and Maternal Morbidity (RANSPRE) (NA)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin 100 mg CI brief — competitive landscape report
- Aspirin 100 mg updates RSS · CI watch RSS
- University Hospital of Ferrara portfolio CI